Topics

ICT Approved to Start US Trials of CD-19 CAR-T for Lymphoma

02:46 EST 5 Dec 2019 | ChinaBio Today

Innovative Cellular Therapeutics (ICT), a Shanghai-US CAR-T company, reported the US FDA approved its IND for ICTCAR014, a next gen CD19-targeting CAR-T cell therapy. ICT said ICTCAR014 expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells. The company expects the US trial will test ICTCAR014 in patients with relapsed or refractory non-Hodgkin lymphoma, including patients with PD-L1 positive tumors. ICT, which has already completed a China trial of ICTCAR014, plans to move its products rapidly through proof-of-concept trials in China and then expand into US and global development. More details....

Share this with colleagues:

Original Article: ICT Approved to Start US Trials of CD-19 CAR-T for Lymphoma

NEXT ARTICLE

More From BioPortfolio on "ICT Approved to Start US Trials of CD-19 CAR-T for Lymphoma"

Quick Search

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...